Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update

Laura Ferrari; Mélanie Claps; Salvatore Grisanti; Alfredo Berruti

doi:10.1016/j.euf.2015.06.005

Systemic Therapy in Locally Advanced or Metastatic Adrenal Cancers: A Critical Appraisal and Clinical Trial Update

Eur Urol Focus. 2016 Feb;1(3):298-300. doi: 10.1016/j.euf.2015.06.005. Epub 2015 Jun 22.

Authors

Laura Ferrari¹, Mélanie Claps¹, Salvatore Grisanti¹, Alfredo Berruti²

Affiliations

¹ Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy.
² Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Spedali Civili Hospital, Brescia, Italy. Electronic address: [email protected].

PMID: 28723406
DOI: 10.1016/j.euf.2015.06.005

Abstract

Mitotane and chemotherapy with etoposide, doxorubicin, and cisplatin plus mitotane (EDP-M) are the only therapies with demonstrated efficacy in advanced adrenocortical carcinoma. Prognostic and predictive factors are needed to identify patients who could obtain the best benefit from these treatments. Despite the strong rationale for their use, clinical trials on molecular targeted therapies have failed to demonstrate that these drugs are efficacious in the management of this extremely rare disease.